Twist Bioscience Corp (NASDAQ:TWST) has received a consensus broker rating score of 1.67 (Buy) from the three analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and two have issued a strong buy recommendation on the company.

Analysts have set a one year consensus target price of $28.50 for the company and are predicting that the company will post ($1.03) EPS for the current quarter, according to Zacks. Zacks has also assigned Twist Bioscience an industry rank of 67 out of 255 based on the ratings given to related companies.

Separately, Zacks Investment Research lowered Twist Bioscience from a “hold” rating to a “sell” rating in a research report on Tuesday, January 29th.

Several institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC bought a new stake in Twist Bioscience during the fourth quarter worth about $26,090,000. Apoletto Ltd bought a new position in Twist Bioscience in the fourth quarter valued at approximately $10,503,000. BlackRock Inc. acquired a new position in shares of Twist Bioscience during the 4th quarter worth approximately $7,782,000. Intellectus Partners LLC acquired a new position in shares of Twist Bioscience during the 4th quarter worth approximately $4,076,000. Finally, Massachusetts Financial Services Co. MA bought a new stake in shares of Twist Bioscience during the 4th quarter worth approximately $5,068,000. 22.74% of the stock is owned by institutional investors.

TWST stock traded up $1.67 during trading hours on Tuesday, reaching $27.41. 187,276 shares of the stock were exchanged, compared to its average volume of 72,326. Twist Bioscience has a 12 month low of $12.38 and a 12 month high of $34.46. The stock has a market cap of $700.45 million and a PE ratio of -1.07. The company has a current ratio of 7.72, a quick ratio of 7.43 and a debt-to-equity ratio of 0.05.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Thursday, February 7th. The company reported ($1.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.33). The firm had revenue of $11.49 million during the quarter, compared to the consensus estimate of $9.70 million. On average, analysts forecast that Twist Bioscience will post -4.18 earnings per share for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Further Reading: What is Cost of Debt?

Get a free copy of the Zacks research report on Twist Bioscience (TWST)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with's FREE daily email newsletter.